Gaertner, Jan ORCID: 0000-0002-1176-3164, Stamer, Ulrike M., Remi, Constanze ORCID: 0000-0001-7655-0306, Voltz, Raymond, Bausewein, Claudia ORCID: 0000-0002-0958-3041, Sabatowski, Rainer ORCID: 0000-0003-2228-3147, Wirz, Stefan, Mueller-Mundt, Gabriele, Simon, Steffen T., Pralong, Anne, Nauck, Friedemann, Follmann, Markus ORCID: 0000-0003-3790-5578, Radbruch, Lukas and Meissner, Winfried (2017). Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat. Med., 31 (1). S. 26 - 35. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-030X

Full text not available from this repository.

Abstract

Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain. Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline Program in Oncology to provide recommendations for the use of dipyrone in cancer pain. Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints were pain intensity, opioid-sparing effects, safety, and quality of life. Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948-2013) and additional hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 representatives of scientific medical societies and 49 experts. Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n=252 patients): dipyrone significantly decreased pain intensity compared to placebo, even if low doses (1.5-2g/day) were used. Higher doses (3x2g/day) were more effective than low doses (3x1g/day), but equally effective as 60mg oral morphine/day. Pain reduction of dipyrone and non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and morphine, the incidence of adverse effects was not increased. Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use, but comparative studies are not available for long-term use.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gaertner, JanUNSPECIFIEDorcid.org/0000-0002-1176-3164UNSPECIFIED
Stamer, Ulrike M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Remi, ConstanzeUNSPECIFIEDorcid.org/0000-0001-7655-0306UNSPECIFIED
Voltz, RaymondUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bausewein, ClaudiaUNSPECIFIEDorcid.org/0000-0002-0958-3041UNSPECIFIED
Sabatowski, RainerUNSPECIFIEDorcid.org/0000-0003-2228-3147UNSPECIFIED
Wirz, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller-Mundt, GabrieleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simon, Steffen T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pralong, AnneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nauck, FriedemannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Follmann, MarkusUNSPECIFIEDorcid.org/0000-0003-3790-5578UNSPECIFIED
Radbruch, LukasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meissner, WinfriedUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-247586
DOI: 10.1177/0269216316655746
Journal or Publication Title: Palliat. Med.
Volume: 31
Number: 1
Page Range: S. 26 - 35
Date: 2017
Publisher: SAGE PUBLICATIONS LTD
Place of Publication: LONDON
ISSN: 1477-030X
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLOOD DYSCRASIAS; ORAL MORPHINE; DIPYRONE; AGRANULOCYTOSIS; PARACETAMOL; METAMIZOL; ACETAMINOPHEN; ANALGESICS; GERMANYMultiple languages
Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & InternalMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/24758

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item